2seventy Bio Stock Investor Sentiment

TSVT Stock  USD 3.99  0.03  0.76%   
Slightly above 53% of 2Seventy Bio's investor base is interested to short. The analysis of the overall investor sentiment regarding 2Seventy Bio suggests that many traders are impartial. 2Seventy Bio's investing sentiment can be driven by a variety of factors including economic data, 2Seventy Bio's earnings reports, geopolitical events, and overall market trends.
  

2Seventy Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 2Seventy Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Novo Nordisk Buys 2seventys Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Yahoo News
over three months ago at benzinga.com         
Novo Nordisk Buys 2seventys Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
benzinga news
over three months ago at businesswire.com         
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to...
businesswire News
over three months ago at businesswire.com         
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to...
businesswire News
over three months ago at news.google.com         
Wedmont Private Capital Makes New 484000 Investment in 2seventy bio, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
2seventy bio, Inc. Receives Consensus Rating of Moderate Buy from Analysts - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Madison Avenue Partners LP Has 7.49 Million Stock Holdings in 2seventy bio, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Birchview Capital LP Trims Stock Position in 2seventy bio, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
2seventy bios Board Elections and Financial Oversight Update - TipRanks.com - TipRanks
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Casdin Capital, Llc of 12050 shares of 2Seventy Bio at 3.93 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Engine Capital Management LP Grows Holdings in 2seventy bio, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Kynam Global Healthcare Master Fund, Lp of 86414 shares of 2Seventy Bio at 5.96 subje...
Macroaxis News
over three months ago at news.google.com         
2seventy bio Downgraded to Sell at The Goldman Sachs Group - Defense World
Google News at Macroaxis
over three months ago at investing.com         
2Seventy Bio stock downgraded by Goldman Sachs amid market challenges
Investing News at Macroaxis
over three months ago at seekingalpha.com         
Goldman cuts 2seventy bio to neutral, cites competition concerns
seekingalpha News
Far too much social signal, news, headlines, and media speculation about 2Seventy Bio that are available to investors today. That information is available publicly through 2Seventy media outlets and privately through word of mouth or via 2Seventy internal channels. However, regardless of the origin, that massive amount of 2Seventy data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 2Seventy Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 2Seventy Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 2Seventy Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 2Seventy Bio alpha.

2Seventy Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
TSVT ALERT Levi Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by 2seventy bio, Inc.
09/26/2024
2
Disposition of 1230 shares by Victoria Eatwell of 2Seventy Bio at 4.6488 subject to Rule 16b-3
10/03/2024
3
TSVT INVESTOR ALERT Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
10/08/2024
4
Did 2seventy bio, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Investigate- TSVT
10/09/2024
5
Disposition of 6159 shares by Gregory Philip D of 2Seventy Bio at 5.4865 subject to Rule 16b-3
10/18/2024
6
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
11/04/2024
7
Morgan Stanleys Strategic Reduction in 2seventy bio Inc Shares
11/07/2024
8
2seventy bio, Inc. Q3 2024 Earnings Call Transcript
11/13/2024
9
US8.25 Thats What Analysts Think 2seventy bio, Inc. Is Worth After Its Latest Results
11/15/2024
10
Disposition of 00 shares by Maus Marcela V. of 2Seventy Bio at 3.3801 subject to Rule 16b-3
11/18/2024
11
2seventy bio, Inc. Reports Q3 Loss, Lags Revenue Estimates - MSN
11/20/2024

Additional Tools for 2Seventy Stock Analysis

When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.